Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signaling
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
· United States · $5.65M USD
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.